## Highlights of This Issue

### SPECIAL FEATURES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>The Importance of Doing Trials Right While Doing the Right Trials</td>
<td>David M. Dilts and Steven K. Cheng</td>
</tr>
<tr>
<td>6</td>
<td>Elusive Extraneural Estrogen Receptors in Breast Cancer</td>
<td>Ellis R. Levin</td>
</tr>
<tr>
<td>9</td>
<td>Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma</td>
<td>Jason J. Luke and F. Stephen Hodi</td>
</tr>
<tr>
<td>15</td>
<td>Molecular Pathways: Targeting Proteasomal Protein Degradation in Cancer</td>
<td>Susan M. Molineaux</td>
</tr>
<tr>
<td>33</td>
<td>BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance</td>
<td>Alexander Marzuka Alcala and Keith T. Flaherty</td>
</tr>
<tr>
<td>40</td>
<td>The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology</td>
<td>Michael Pollak</td>
</tr>
<tr>
<td>51</td>
<td>Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale</td>
<td>Edina Komlodi-Pasztor, Dan L. Sackett, and Antonio Tito Fojo</td>
</tr>
<tr>
<td>64</td>
<td>Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?</td>
<td>Len Neckers and Paul Workman</td>
</tr>
</tbody>
</table>

### HUMAN CANCER BIOLOGY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>77</td>
<td>Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy</td>
<td>Clinton D. Kemp, Mahadev Rao, Sichuan Xi, Suzanne Inchauste, Haresh Mani, Patricia Fetsch, Armando Filie, Mary Zhang, Julie A. Hong, Robert L. Walker, Yuelin J. Zhu, R. Taylor Ripley, Aarti Mathur, Fang Liu, Maosheng Yang, Paul A. Meltzer, Victor E. Marquez, Assunta De Rienzo, Raphael Bueno, and David S. Schrump</td>
</tr>
<tr>
<td>105</td>
<td>Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness</td>
<td>Dieter Lemke, Philipp-Niclas Pfenning, Felix Sahm, Ann-Catherine Klein, Tore Kempf, Uwe Warnken, Martina Schonzer, Ruxandra Tudoran, Michael Weller, Michael Platten, and Wolfgang Wick</td>
</tr>
</tbody>
</table>

### CANCER THERAPY: PRECLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
Phenylarsine Oxide Induces Apoptosis in Bax- and Bak-Deficient Cells through Upregulation of Bim
Biyun Ni, Qi Ma, Baowei Li, Lixia Zhao, Yong Liu, Yushan Zhu, and Quan Chen

Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy
Rajat Singh, Yujian Zhang, Ira Pastan, and Robert J. Kreitman

Modulation of the Tumor Microvasculature by Phosphoinositide-3 Kinase Inhibition Increases Doxorubicin Delivery In Vivo
Naseer Qayum, Jaehong Im, Michael R. Stratford, Eric J. Bernhard, W. Gillies McKenna, and Ruth J. Muschel

Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells
Dimpy Koul, Jun Fu, Ruijun Shen, Tiffany A. LaFortune, Shuzhen Wang, Ningyi Tiao, Yong-Wan Kim, Juinn-Lin Liu, Deepthi Ramnarian, Ying Yuan, Carlos Garcia-Echeverria, Sauveur-Michel Maira, and W.K. Alfred Yung

Validation of Genetic Sequence Variants as Prognostic Factors in Early-Stage Head and Neck Squamous Cell Cancer Survival
Abul Kalam Azad, Isabelle Bairati, Elodie Samson, Dangxiao Cheng, Maryam Mirshams, Xin Qu, Sevtap Savas, John Waldron, Changshu Wang, David Goldstein, Wei Xu, Francois Meyer, and Geoffrey Liu

Noninvasive Detection of Breast Cancer Lymph Node Metastasis Using Carbonic Anhydrases IX and XII Targeted Imaging Probes

Early [18F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung
Ryo Takahashi, Haruhiko Hirata, Isao Tachibana, Eku Shimosegawa, Atsuo Inoue, Izumi Nagatomo, Yoshito Takeda, Hiroshi Kida, Sho Goya, Takashi Kijima, Mitsuhiro Yoshida, Toru Kumagai, Atsushi Kumanogoh, Meinoshin Okumura, Jun Hatazawa, and Ichiro Kawase

In Vivo Positron Emission Tomography Imaging of Protease Activity by Generation of a Hydrophobic Product from a Noninhibitory Protease Substrate

CANCER THERAPY: CLINICAL
A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
Michelle A. Fanale, Andres Forero-Torres, Joseph D. Rosenblatt, Ranjana H. Advani, Anna R. Franklin, Dana A. Kennedy, Tae H. Han, Eric L. Sievers, and Nancy L. Bartlett

Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups

IMAGING, DIAGNOSIS, PROGNOSIS
Validation of Genetic Sequence Variants as Prognostic Factors in Early-Stage Head and Neck Squamous Cell Cancer Survival
Abul Kalam Azad, Isabelle Bairati, Elodie Samson, Dangxiao Cheng, Maryam Mirshams, Xin Qu, Sevtap Savas, John Waldron, Changshu Wang, David Goldstein, Wei Xu, Francois Meyer, and Geoffrey Liu

Noninvasive Detection of Breast Cancer Lymph Node Metastasis Using Carbonic Anhydrases IX and XII Targeted Imaging Probes

Lymphatic Invasion Is Independently Prognostic of Metastasis in Primary Cutaneous Melanoma
Xiaowei Xu, Lianjun Chen, DuPont Guerry, Peter R. Dawson, Wei-ting Hwang, Patricia VandeBelle, David E. Elder, Paul J. Zhang, Michael E. Ming, Lynn Schuchter, and Phyllis A. Gimotty

Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups

See commentary p. 3
Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1
Jean Philippe Arnault, Christine Mateus, Bernard Escudier, Gorana Tomasic, Janine Wechsler, Emilie Hollville, Jean-Charles Soria, David Malka, Alain Sarasin, Magalie Larcher, Jocelyne André, Nym Kamsu-Kom, Lise Boussenart, Ludovic Lacroix, Alain Spatz, Alexander M. Eggermont, Sabine Druillement, Stephan Vagner, Alain Eychene, Nicolas Dumaz, and Caroline Robert

Concurrent Temozolomide and Dose-Escalated Intensity-Modulated Radiation Therapy in Newly Diagnosed Glioblastoma
Christina I. Tsien, Doris Brown, Daniel Normolle, Matthew Schipper, Morand Piert, Larry Junck, Jason Heth, Diana Gomez-Hassan, Randall K. Ten Haken, Thomas Chenevert, Yue Cao, and Theodore Lawrence

Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer
Sonali Gupta, Dipankar Pramanik, Radha Mukherjee, Nathaniel R. Campbell, Sathyarayanan Elumalai, Roeland F. de Wilde, Seung-Mo Hong, Michael G. Goggins, Ana De Jesus-Acosta, Daniel Laheru, and Anirban Maitra

TP53 Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence
Heath D. Skinner, Vlad C. Sandulache, Thomas J. Ow, Raymond E. Meyn, John S. Yordy, Beth M. Beadle, Alison L. Fitzgerald, Uma Giri, K. Kian Ang, and Jeffrey N. Myers

Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial
Annette M. Lim, Danny Rischin, Richard Fisher, Hongbin Cao, Kathleen Kwok, Daniel Truong, Grant A. McArthur, Richard J. Young, Amato Giaccia, Lester Peters, and Quynh-Thu Le

VKX3.1 Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy
Jennifer A. Locke, Gaetano Zafarana, Adrian S. Ishkanian, Michael Milosevic, John Thoms, Cherry L. Have, Chad A. Mallof, Wan L. Lam, Jeremy A. Squire, Melanie Pintilie, Jenna Sykes, Varune Rohan Rammarine, Alice Meng, Omer Ahmed, Igor Jurisica, Theo van der Kwast, and Robert G. Bristow

LETTER TO THE EDITOR

A CDD Polymorphism as Predictor of Capecitabine-Induced Hand-Foot Syndrome—Letter
Joseph Ciccolini, Alexandre Evrard, and Bruno Lacarelle

CORRECTIONS

Correction: Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance

Correction: ABCB1 (MDR1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy
ABOUT THE COVER

B7H3 represents a novel driver of gliomagenesis by mediating an immunosuppressive and proinvasive phenotype in glioblastoma. Immunofluorescence demonstrates the perivascularly (alpha-SMA staining; red) enhanced expression of B7H3 (vesicular distribution; green) in human glioblastoma tissue (nuclei staining; blue). For details, see the article by Lemke and colleagues on page 105 of this issue.